MARKET

ZYNE

ZYNE

Zynerba Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.230
-0.090
-2.08%
After Hours: 4.130 -0.1 -2.36% 17:36 09/17 EDT
OPEN
4.290
PREV CLOSE
4.320
HIGH
4.380
LOW
4.070
VOLUME
2.91M
TURNOVER
--
52 WEEK HIGH
9.00
52 WEEK LOW
3.150
MARKET CAP
174.49M
P/E (TTM)
-3.9004
1D
5D
1M
3M
1Y
5Y
Zynerba Initiates Pivotal Phase 3 Study for Zygel in Treatment of Fragile X Symptoms
MT Newswires · 4d ago
BRIEF-Zynerba Pharmaceuticals Initiates Pivotal Trial Of Zygel In Fragile X Syndrome
reuters.com · 4d ago
Zynerba Pharmaceuticals Initiates RECONNECT, a Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome
Trial will evaluate the efficacy and safety of Zygel in children and adolescents with Fragile X Syndrome Topline results expected in second half of 2023 DEVON, Pa., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader...
GlobeNewswire · 4d ago
Zynerba Stock Moves Higher On Long-Term Zygel Data In Autistic Children
Benzinga · 09/09 15:06
Zynerba Pharmaceuticals Presents Longer Term Tolerability And Efficacy Data Of Zygel In Children and Adolescents with Autism Spectrum Disorder at The Society for the Study of Behavioural Phenotypes Conference 2021
Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today presented data from the Phase 2
Benzinga · 09/09 11:16
BRIEF-Zynerba Pharmaceuticals Announces Publication Of Results Of Phase 2 Study Of Zygel In Children And Adolescents With Developmental And Epileptic Encephalopathies
reuters.com · 09/07 11:21
Zynerba Pharmaceuticals Announces Publication of Results of Phase 2 BELIEVE Open-Label Study of Zygel™ in Children and Adolescents with Developmental and Epileptic Encephalopathies (DEE) in JAMA Network Open
DEVON, Pa., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the publica...
GlobeNewswire · 09/07 11:00
Zynerba Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
DEVON, Pa., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armand...
GlobeNewswire · 09/02 11:30
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ZYNE. Analyze the recent business situations of Zynerba Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ZYNE stock price target is 7.63 with a high estimate of 9.00 and a low estimate of 4.500.
EPS
Institutional Holdings
Institutions: 121
Institutional Holdings: 14.92M
% Owned: 36.17%
Shares Outstanding: 41.25M
TypeInstitutionsShares
Increased
24
7.06M
New
10
317.75K
Decreased
16
1.54M
Sold Out
12
235.27K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.49%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Chairman/Chief Executive Officer/Director
Armando Anido
President
Terri Sebree
Chief Financial Officer/Vice President
James Fickenscher
Vice President/General Counsel/Secretary
Suzanne Hanlon
Vice President - Business Development
Brian Rosenberger
Lead Director/Independent Director
Warren Cooper
Independent Director
John Butler
Independent Director
William Federici
Independent Director
Daniel Kisner
Independent Director
Kenneth Moch
Independent Director
Pamela Stephenson
No Data
  • All
  • Financials
  • Insiders
More
About ZYNE
Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. ZYN002 is in Phase II clinical development in patients with refractory epilepsy, in patients with osteoarthritis of the knee, as well as in patients with Fragile X syndrome. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through the skin and into the circulatory system through a patch. ZYN001 is targeting two pain indications, fibromyalgia and peripheral neuropathic pain.

Webull offers kinds of Zynerba Pharmaceuticals Inc stock information, including NASDAQ:ZYNE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZYNE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ZYNE stock methods without spending real money on the virtual paper trading platform.